Introduction to Blood Physiology and Pathology
Understanding the complex interplay between blood components, their regulatory mechanisms, and the diseases that disrupt them is essential for any medical professional. This course reviews the most frequently tested concepts in general medicine, focusing on anemia, coagulation, and the hormonal control of erythropoiesis. By the end of the module, you will be able to identify key laboratory findings, explain pathophysiological mechanisms, and recall clinical pearls that improve diagnostic accuracy.
Megaloblastic Anemia: Vitamin B12 Deficiency
Clinical Presentation
Patients typically present with fatigue, pallor, and a low reticulocyte count. Neurological symptoms such as paresthesia or gait disturbances may also appear, reflecting the unique role of vitamin B12 in myelin synthesis.
Pathogenesis
Vitamin B12 (cobalamin) is required for DNA synthesis in rapidly dividing cells, especially erythroid precursors. Deficiency leads to asynchronous nuclear-cytoplasmic maturation, producing large, immature red cells (macrocytes) and the characteristic megaloblasts in the bone marrow.
Key Diagnostic Clues
- Elevated mean corpuscular volume (MCV > 100 fL)
- Hypersegmented neutrophils on peripheral smear
- Low serum vitamin B12 levels; elevated methylmalonic acid
- Normal iron studies (distinguishes from iron‑deficiency anemia)
Common Causes
- Autoimmune gastritis leading to loss of intrinsic factor
- Dietary deficiency (strict vegan diet)
- Malabsorption syndromes (e.g., Crohn's disease affecting the ileum)
Management Overview
Intramuscular cyanocobalamin or high‑dose oral B12 is administered, followed by monitoring of hematologic response and neurological recovery.
Plasma Proteins and Oncotic Pressure in Hemorrhage
Why Albumin Drops First
During a severe bleed, the body loses whole blood, including plasma proteins. Albumin is the most abundant plasma protein and contributes ~70% of the oncotic pressure that retains fluid within the vascular compartment. Its rapid decrease leads to a measurable fall in oncotic pressure, promoting interstitial edema.
Other Proteins and Their Roles
- Transferrin – iron transport; changes are slower.
- Globulin α1 – acute‑phase reactant; may actually increase during inflammation.
- Fibrinogen – essential for clot formation; levels can rise as part of the acute‑phase response.
Clinical Implications
Monitoring serum albumin after trauma helps guide fluid resuscitation and predicts the risk of third‑spacing. Albumin replacement may be considered in massive transfusion protocols.
Persistent Fetal Hemoglobin (HbF) and Beta‑Thalassemia
HbF (α2γ2) is the predominant hemoglobin in the fetus and normally declines to <2% of total hemoglobin by six months of age. When HbF remains elevated beyond infancy, a hemoglobinopathy is often responsible.
Beta‑Thalassemia: The Genetic Basis
Beta‑thalassemia results from mutations that reduce or abolish synthesis of the β‑globin chain. The imbalance between α‑ and β‑chains triggers compensatory up‑regulation of γ‑globin production, thereby increasing HbF levels.
Key Laboratory Findings
- Elevated HbF (often >5‑10% in carriers, >20% in major disease)
- Microcytic, hypochromic anemia with high red‑cell distribution width (RDW)
- Increased reticulocyte count reflecting ineffective erythropoiesis
- Iron overload in transfusion‑dependent patients
Mnemonic and Visual Aid
Riepilogo dei punti chiave
- HbF (emoglobina fetale) è normalmente alta solo nei neonati e diminuisce entro i primi mesi di vita.
- Nel beta talassemia la sintesi della catena β è ridotta o assente, perciò il corpo compensa producendo più catene γ, mantenendo elevati i livelli di HbF.
- Le altre condizioni elencate (sickle cell, alfa talassemia, sferocitosi ereditaria) non causano un aumento persistente di HbF.
Come ricordarlo
- Mnemonica: “Beta‑talassemia → B per “Beta” e “B” per “Beta‑globina bassa, quindi più B‑F (HbF)”.
- Consiglio: Immagina un “cantiere” dove la produzione di mattoni β è ferma; il lavoro passa a usare i mattoni γ (HbF) per completare la costruzione del sangue.
Platelets in the Early Phase of Hemostasis
Primary Hemostasis Overview
When the endothelium is damaged, the subendothelial matrix (collagen, von Willebrand factor) becomes exposed. Platelets rapidly adhere to this surface, forming a temporary “white thrombus.” This adhesion is mediated by glycoprotein Ib‑IX‑V binding to von Willebrand factor and by integrin αIIbβ3 interacting with collagen.
Key Functions of Platelets
- Adhesion to damaged endothelium – the first step in clot formation.
- Release of ADP and thromboxane A2 to recruit additional platelets.
- Provision of a phospholipid surface for the secondary coagulation cascade.
Common Misconceptions
Platelets do not convert prothrombin to thrombin, synthesize fibrinogen, or directly recruit leukocytes in the initial phase. Their primary role is mechanical plugging and signaling for amplification.
Chronic Gastritis and Macrocytic Anemia
Link Between Gastritis and Vitamin B12
Chronic gastritis, especially autoimmune (pernicious) gastritis, destroys parietal cells that produce intrinsic factor. Without intrinsic factor, dietary vitamin B12 cannot be absorbed in the terminal ileum, leading to a classic macrocytic, megaloblastic anemia.
Diagnostic Approach
- Serum B12 level < 200 pg/mL
- Positive anti‑parietal cell or anti‑intrinsic factor antibodies
- Elevated methylmalonic acid and homocysteine
Treatment Strategy
Intramuscular cyanocobalamin is the preferred route because oral absorption is impaired. Lifelong therapy is often required.
Intrinsic Pathway of Coagulation: First Activated Factor
Sequence of Activation
The intrinsic pathway is initiated when blood contacts negatively charged surfaces (e.g., exposed collagen). The first factor to become activated is Factor XII (Hagemann factor), which then activates Factor XI, leading downstream to the common pathway.
Clinical Relevance
- Deficiency of Factor XII does not cause bleeding but may prolong activated partial thromboplastin time (aPTT).
- Contact activation is the basis for many laboratory coagulation assays.
Erythropoietin (EPO) – The Hypoxia‑Driven Cytokine
Physiological Role
Erythropoietin, a glycoprotein hormone produced primarily by renal peritubular fibroblasts, is the principal cytokine that stimulates erythropoiesis in response to tissue hypoxia. It binds to the EPO receptor on erythroid progenitors, preventing apoptosis and promoting proliferation.
Regulatory Mechanisms
- Hypoxia‑inducible factor (HIF) stabilizes under low oxygen, up‑regulating EPO gene transcription.
- Chronic kidney disease reduces EPO production, leading to anemia of chronic disease.
Therapeutic Applications
Recombinant EPO (epoetin alfa, darbepoetin) is used to treat anemia in renal failure, chemotherapy‑induced anemia, and certain HIV patients.
Summary of Core Concepts
- Vitamin B12 deficiency is the most common cause of megaloblastic anemia with low reticulocytes.
- Albumin concentration falls first during massive hemorrhage, reducing oncotic pressure.
- Persistent high HbF points to beta‑thalassemia, which shows elevated HbF levels.
- Platelets adhere to damaged endothelium forming a white thrombus in early hemostasis.
- Chronic gastritis leads to loss of intrinsic factor, causing B12‑deficiency macrocytic anemia.
- In the intrinsic coagulation cascade, Factor XII is the initiating factor.
- Erythropoietin (EPO) is the key cytokine that drives red‑cell production under hypoxic conditions.
Mastering these topics will improve your ability to diagnose and manage common hematologic and hemostatic disorders encountered in everyday clinical practice.
